Buchumschlag

Outcomes and recurrence pattern analysis of intensity modulated chemoradiotherapy in nasopharyngeal cancer: a retrospective study from Heidelberg University Hospital

Background: To evaluate treatment outcomes, toxicity, and recurrence patterns by dose level in nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiotherapy (IMRT) and weekly cisplatin.Methods: We retrospectively analyzed 48 NPC patients treated between 2005 and 2019 with IMR...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bauer, Lukas (VerfasserIn) , Regnery, Sebastian (VerfasserIn) , Deng, Maximilian (VerfasserIn) , Stritzke, Florian (VerfasserIn) , Schröter, Philipp (VerfasserIn) , Franke, Henrik (VerfasserIn) , Netzer, Nils (VerfasserIn) , Uzun-Lang, Kristin (VerfasserIn) , Kozyra, Katharina (VerfasserIn) , Thölken, Rubens (VerfasserIn) , Debus, Jürgen (VerfasserIn) , Held, Thomas (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 08 December 2025
In: Radiation oncology
Year: 2025, Jahrgang: 20, Pages: 1-10
ISSN:1748-717X
DOI:10.1186/s13014-025-02769-7
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s13014-025-02769-7
Volltext
Verfasserangaben:Lukas Bauer, Sebastian Regnery, Maximilian Y. Deng, Florian Stritzke, Philipp Schröter, Henrik Franke, Nils B. Netzer, Kristin Uzun-Lang, Katharina Weusthof, Rubens Thoelken, Jürgen Debus and Thomas Held
Beschreibung
Zusammenfassung:Background: To evaluate treatment outcomes, toxicity, and recurrence patterns by dose level in nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiotherapy (IMRT) and weekly cisplatin.Methods: We retrospectively analyzed 48 NPC patients treated between 2005 and 2019 with IMRT and weekly cisplatin (40 mg/m²). The planning target volume (PTV) received a median total dose of 57.6 Gy (1.8 Gy/fraction) with a simultaneous integrated boost to the primary tumor and nodal metastases up to 70.4 Gy. To assess recurrence patterns, follow-up imaging was deformably co-registered with planning CTs (pCT), and recurrent gross tumor volumes (rGTVs) were delineated and mapped to pCTs. Recurrences were categorized using a centroid-based system into five types: A (central high-dose), B (peripheral high-dose), C (central intermediate-/low-dose), D (peripheral intermediate-/low-dose), and E (extraneous dose). Results: With a median follow-up of 73 months (range 24–156), 9 patients (19%) had died. The 3-, 5-, and 10-year overall survival rates were 98%, 96%, and 67%, respectively. Local control rates (LCR) at 2, 3, and 5 years were 92%, 89%, and 89%; regional control was 96%, 94%, and 94%; and distant control was 92%, 89%, and 89%. Treatment was well tolerated, with no grade ≥ 4 toxicities. Grade 3 acute toxicities occurred in 23 patients (48%), most commonly dysphagia, with nearly all resolving within 90 days. Among treatment failures, distant metastases (13%) and local relapses (10%) were most frequent. Of 8 local and/or regional recurrences analyzed, 2 were type A (central high-dose), 3 type B (“marginal”), 2 type C (central intermediate-/low-dose), and 1 type E (“out-of-field”). Conclusion: IMRT with weekly cisplatin yields excellent survival and locoregional control with acceptable toxicity in NPC. Distant metastasis as one of the predominant failure patterns highlights the need for more effective systemic therapies. Most local recurrences arose within high-dose areas, suggesting a potential opportunity for treatment optimization.
Beschreibung:Veröffentlicht: 08. Dezember 2025
Gesehen am 26.02.2026
Beschreibung:Online Resource
ISSN:1748-717X
DOI:10.1186/s13014-025-02769-7

Ähnliche Einträge